Capricor Therapeutics Announces Intent to File Biologics License ...
网页2 天之前 · SAN DIEGO, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, announced today, following recent meetings with the U.S. Food and Drug Administration (FDA), its intent to file a Biologics …
Capricor to seek deramiocel’s FDA approval for DMD heart disease
网页15 小时之前 · Capricor Therapeutics will soon begin filing an application seeking U.S. approval of its cell therapy deramiocel for cardiomyopathy, a disease of the heart’s muscle, in people with Duchenne muscular dystrophy (DMD). Following recent meetings with the U.S. Food and Drug Administration (FDA), Capricor will file a rolling application, meaning ...
Capricor Therapeutics Shares Rise in Premarket on Plans to File ...
网页2 天之前 · Capricor said that the data in the filing will be based on existing cardiac data from its phase 2 trials. Write to Adriano Marchese at [email protected] About Dow Jones Newswires
Capricor Therapeutics to Provide Duchenne Muscular Dystrophy …
网页3 天之前 · Capricor will host a conference call and webcast at 8:30 a.m. ET on Tuesday, September 24, 2024. To participate in the conference call, please dial 1-800-717-1738 (domestic/toll-free) or 1-646-307 ...
Capricor surges on plans to seek FDA approval for lead asset - MSN
网页S hares of Capricor Therapeutics (NASDAQ: CAPR) surged in the morning hours on Tuesday after the cell therapy developer announced plans to seek FDA approval for its lead candidate deramiocel (CAP ...
Capricor to Submit BLA for Approval of Dermiocel in Treating …
网页2 天之前 · News release. Capricor Therapeutics. September 24, 2024. Accessed September 25, ... Capricor Therapeutics announces long-term benefit of deramiocel (CAP-1002) in both skeletal muscle and cardiac function in the HOPE-2 OLE study in Duchenne muscular dystrophy. News release. June 28, 2024.
Press Releases :: Capricor Therapeutics, Inc. (CAPR)
网页2024年7月1日 · Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy.
News & Events :: Capricor Therapeutics, Inc. (CAPR)
网页2024年6月6日 · Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy.
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 ...
网页SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today its financial results for the fourth quarter and full year ended December 31, 2023 and …
Capricor Therapeutics to Provide Duchenne Muscular Dystrophy …
网页4 天之前 · Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.
跳至内容